News for 'pharmaceutical drugs'

COVID: 'Treatment gets very challenging'

COVID: 'Treatment gets very challenging'

Rediff.com23 Jul 2021

'When you are on these drugs, there is a possibility that you come to the hospital late, just by virtue of the fact that you believe that things are going to turn around, because you are on all these medicines.'

Lupin launches generic Ciprofloxacin in US market

Lupin launches generic Ciprofloxacin in US market

Rediff.com13 Jun 2014

The company's US subsidiary, Lupin Pharmaceuticals Inc has launched its Ciprofloxacin for oral suspension in the US market in the strengths of 5 g/100 mL (250mg/5 mL) and 10 g/100 mL (500 mg/5 mL), Lupin said in a statement.

India lifts curbs on exports of 13 active pharma ingredients

India lifts curbs on exports of 13 active pharma ingredients

Rediff.com7 Apr 2020

A leading exporter said, there is enough stock of paracetamol in the country. At present, the US, which has become the epicentre of the COVID-19 outbreak, needs paracetamol. He further said India would lose its credibility as the "pharmacy of the world" if it adopts protectionist policies during such a crisis.

US FDA conducts surprise inspection of Dr Reddy's Vizag plant

US FDA conducts surprise inspection of Dr Reddy's Vizag plant

Rediff.com20 Nov 2014

The FDA has been tightening its monitoring of Indian pharma majors over compliance issues. Surprise plant inspections and import alerts have been frequent outcomes

Masks, hand sanitiser declared 'essential commodities'

Masks, hand sanitiser declared 'essential commodities'

Rediff.com14 Mar 2020

These items will remain under essential commodities segment till June-end, a move aimed at ensuring availability at reasonable prices and cracking down on hoarders/black marketeers.

FDA warns India's Emcure Pharma, cites repeated data fudging at plant

FDA warns India's Emcure Pharma, cites repeated data fudging at plant

Rediff.com17 Mar 2016

It is one of 42 drug-making factories in India that the FDA has banned in recent years

Column: What was the Novartis case really about?

Column: What was the Novartis case really about?

Rediff.com8 Apr 2013

The drug Glivec was a genuinely new and important discovery deserving of patent protection.

Sun Pharma's US subsidiary to cut jobs

Sun Pharma's US subsidiary to cut jobs

Rediff.com30 Jul 2009

Earlier last month US FDA officials had seized drug products manufactured by Caraco Pharmaceutical at its Michigan facilities in Detroit, Farmington Hills, and Wixom, alleging violation in good manufacturing practice.

NPPA slaps Rs 300-crore penalty on Novartis

NPPA slaps Rs 300-crore penalty on Novartis

Rediff.com13 Oct 2014

Drug major Novartis has been slapped with a Rs 300-crore penalty by drug regulator NPPA for overcharging consumers on sale of Voveran, its best-selling painkiller medicine.

Vaccine will be available to all

Vaccine will be available to all

Rediff.com17 Dec 2020

The vaccine would be first made available to the vulnerable population and eventually, it would be available in the private market for all.

NPPA heat on hospitals for failing to provide stent details

NPPA heat on hospitals for failing to provide stent details

Rediff.com7 Mar 2017

The regulator is now probing 24 hospitals, including Max Hospital in New Delhi and Lilavati in Mumbai, for allegedly overcharging patients for stents

Hydroxychloroquine consignment from India arrives in US

Hydroxychloroquine consignment from India arrives in US

Rediff.com12 Apr 2020

Hydroxychloroquine has been identified by the US Food and Drug Administration as a possible treatment for the COVID-19 and it is being tested on more than 1,500 coronavirus patients in New York.

India's medicine man strikes again

India's medicine man strikes again

Rediff.com15 May 2012

To some -- especially western drug companies -- he is a 'pirate'. To others, mostly those in developing countries, he is an unparalleled hero. Either way, Yusuf Hamied, 75, is perhaps the most talked about man in pharmaceutical circles in the last decade.

Ranbaxy resumes supply of Atorvastatin tablets in US

Ranbaxy resumes supply of Atorvastatin tablets in US

Rediff.com1 Apr 2013

The company had stopped production of generic version of cholesterol lowering drug Lipitor last year as it investigated the issue of potential glass particles in certain lots of the drug.

Gilead to allow 5 Indian firms to sell hepatitis generics in 90 countries

Gilead to allow 5 Indian firms to sell hepatitis generics in 90 countries

Rediff.com15 Sep 2014

Among the companies likely to sign deals with Gilead are Cadila, Hetero, Strides Arcolab and Mylan, while Cipla is expected to earn active pharmaceutical ingredient rights.

Rakesh Jhunjhunwala rejigs portfolio in Q2; ups stake in Lupin, Tata Motors

Rakesh Jhunjhunwala rejigs portfolio in Q2; ups stake in Lupin, Tata Motors

Rediff.com30 Oct 2020

The duo bought additional shares in pharmaceutical companies Lupin and Jubilant Life Sciences, along with Agro Tech Foods and NCC during Q2FY21

Glaxo lines up R&D push

Glaxo lines up R&D push

Rediff.com20 Mar 2004

Pharma cos on DMF filing spree

Pharma cos on DMF filing spree

Rediff.com12 Jan 2005

JB Chem files 1st ANDA, US FDA

JB Chem files 1st ANDA, US FDA

Rediff.com16 Jan 2003

JB Chemicals & Pharmaceuticals Ltd on Thursday announced the filing of its first Abbreviated New Drug Application with the United States Food and Drug Administration.

Getting coronavirus 'a blessing in disguise': Trump

Getting coronavirus 'a blessing in disguise': Trump

Rediff.com8 Oct 2020

'I want everybody to be given the same treatment as your president because I feel great. I feel like perfect'

Wockhardt told to pull out analgesic batches

Wockhardt told to pull out analgesic batches

Rediff.com14 Feb 2013

Regulator mentions Wockhardt as manufacturer but firm says it only markets drug.

No sabotage at Toansa plant, says Ranbaxy

No sabotage at Toansa plant, says Ranbaxy

Rediff.com12 Feb 2014

Company is among the few companies in the sector getting pulled up by FDA for violations at its factories in India.

Tatas mull entry into biotech

Tatas mull entry into biotech

Rediff.com12 Mar 2005

Why Baichung wants to eject Chamling from office

Why Baichung wants to eject Chamling from office

Rediff.com18 Jun 2018

'Chamling's legacy is toxic.' '7 out of 10 teenagers in Sikkim abuse drugs.' 'The youth are dying and the future looks bleak.'

Natco, Cipla up after SC dismisses Novartis plea

Natco, Cipla up after SC dismisses Novartis plea

Rediff.com1 Apr 2013

In a landmark judgment that has the potential to change the direction of India's pharmaceutical business, the Supreme Court said on Monday that the drug failed to qualify for a patent according to Indian law.

Taro faces ban on products in US market

Taro faces ban on products in US market

Rediff.com11 Feb 2009

If Taro fails to address the issues raised by the US Food and Drug Administration, it may face ban on many of its products in the US market, made from the facility at Ontorio, Canada. If Taro fails to address the issues raised by the US Food and Drug Administration, it may face ban on many of its products in the US market, made from the facility at Ontorio, Canada. If Taro fails to address the issues raised by the US FDA, it may face ban on many of its products.

GSK India clones local strategy

GSK India clones local strategy

Rediff.com21 Feb 2005

30 groups in India trying to develop COVID-19 vaccine: PSA

30 groups in India trying to develop COVID-19 vaccine: PSA

Rediff.com28 May 2020

Without naming the entity, he said some players are at a pre-clinical stage and may reach the clinical stage by October. Responding to a question on absence of a vaccine currently and the prospects in the next few months as the lockdown eases, VijayRaghvan emphasised on aggressive rapid testing and tracking.

US FDA likely to inspect new Visakhapatnam arm of Divi's Labs in Jan

US FDA likely to inspect new Visakhapatnam arm of Divi's Labs in Jan

Rediff.com31 Dec 2013

The move assumes significance because a go-ahead from the US Food and Drug Administration for the new unit in Visakhapatnam is likely to give a huge boost to the company's revenues in upcoming quarters.

Govt panel recommends nod for phase 2/3 trials of Covovax on kids

Govt panel recommends nod for phase 2/3 trials of Covovax on kids

Rediff.com27 Jul 2021

An expert panel of India's Central Drug Authority on Tuesday recommended granting permission to Serum Institute of India (SII) for conducting phase 2/3 trials of Covid vaccine Covovax on children aged 2 to 17 years with certain conditions, official sources said.

Glenmark initiates studies to develop new molecule

Glenmark initiates studies to develop new molecule

Rediff.com4 Feb 2013

It can possibly be used to treat diseases like Arthritis and bowel disease.

Pharma stocks on a booster dose

Pharma stocks on a booster dose

Rediff.com1 Mar 2014

Better-than-expected financial results in Q3 due to higher revenue growth and margins in key markets fuel the rally

How safe are cheap medicines made in India?

How safe are cheap medicines made in India?

Rediff.com11 Mar 2016

An International Policy Network report in 2010 found that seven per cent of drugs bought from wholesale traders were substandard, and 3.6 per cent of the drugs from traders contained no active ingredient whatsoever.

Why draft pharma policy may take time to see light of day

Why draft pharma policy may take time to see light of day

Rediff.com25 Sep 2018

Some of the proposals (for example trade margin calculation for imported medical devices) were not approved by the PMO and were sent back for revisions.

Big Pharma pushes for US action against India

Big Pharma pushes for US action against India

Rediff.com6 Feb 2014

Emerging markets, from South Africa to China and India, are battling to bring down healthcare costs.

Patent row: HC refuses interim relief to Merck

Patent row: HC refuses interim relief to Merck

Rediff.com5 Apr 2013

The development assumes significance as on Monday the Supreme Court had rejected the plea of Novartis AG for patent protection of its anti-cancer drug Glivec.

NPPA pulls up cipla, Ranbaxy for overcharging

NPPA pulls up cipla, Ranbaxy for overcharging

Rediff.com10 Dec 2010

Leading pharmaceutical firms such as Cipla and Ranbaxy are among the firms pulled up by the drug price regulator National Pharmaceuticals Pricing Authority (NPPA) for overcharging.

Indian companies not singled out for inspections: USFDA

Indian companies not singled out for inspections: USFDA

Rediff.com18 Mar 2015

A global policy would reward firms which strive for higher quality.